

BME - GROWTH
 Palacio de la Bolsa
 Plaza de la Lealtad, 1
 28014 Madrid

Alicante, 5th January 2022

COMUNICACION- OTHER RELEVANT INFORMATION- FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Under the provisions of article 17 of the Regulation (EU) No. 596/2014 on market abuse, and article 228 of the consolidated text of the Spanish Securities Market Law, approved by the Royal Legislative Decree 4/2015, of 23rd October, and related provisions, as well as in the Circular 3/2020 of BME Growth, we inform you about the following information related to the company FACEPHI BIOMETRIA, S.A. (hereinafter “FacePhi” or “the Company”, interchangeably).

The following shows those shareholders whose percentage of participation, direct or indirect, in the Company are equal to or greater than 5% as of December 31st. 2021:

	Direct Participation	Indirect Participation
Salvador Martí Varó	8,61%	0.08%
Javier Mira Miró	6.29%*	0%
Juan Alfonso Ortiz Company	6.49%**	0.79%
José Cristóbal Callado Solana	6.02%	0.00%

* 7.46% considering the 141,470 y 35,196 lent shares given to Nice & Green according to the Market Notice published on September 18, 2019 and the Privileged Information published on December 15, 2020, respectively.

** 7.66% considering the 150,586 y 26,080 lent shares given to Nice & Green according to the Market Notice published on September 18, 2019 and the Privileged Information published on December 15, 2020, respectively.

These percentages are based on the 15.134.322 shares in which the company’s capital is divided to this day.

The Company’s Board of Directors is not aware of the existence of other shareholders whose possession exceed the 5%.



In compliance with Circular 3/2020 of the segment BME Growth of BME MTF Equity, it is expressly stated that the information hereby communicated has been produced under the sole responsibility of the company and its administrators.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró

Chairman of the Board of Directors